Abivax ADR (ABVX) concluded trading on Wednesday at a closing price of $68.6, with 27.68 million shares of worth about $1.9 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 976.92% during that period and on July 23, 2025 the price saw a gain of about 586.00%. Currently the company’s common shares owned by public are about 63.35M shares, out of which, 55.63M shares are available for trading.
Stock saw a price change of 594.33% in past 5 days and over the past one month there was a price change of 1022.75%. Year-to-date (YTD), ABVX shares are showing a performance of 453.23% which increased to 837.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.77 but also hit the highest price of $13.17 during that period. The average intraday trading volume for Abivax ADR shares is 416.25K. The stock is currently trading 496.96% above its 20-day simple moving average (SMA20), while that difference is up 704.91% for SMA50 and it goes to 769.16% higher than SMA200.
Abivax ADR (NASDAQ: ABVX) currently have 63.35M outstanding shares and institutions hold larger chunk of about 39.28% of that.
The stock has a current market capitalization of $4.35B and its 3Y-monthly beta is at 0.29. It has posted earnings per share of -$3.02 in the same period. It has Quick Ratio of 1.82 while making debt-to-equity ratio of 2.37. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABVX, volatility over the week remained 7.87% while standing at 7.16% over the month.
Stock’s fiscal year EPS is expected to rise by 2.77% while it is estimated to increase by 20.96% in next year. EPS is likely to grow at an annualized rate of 4.19% for next 5-years, compared to annual growth of -1.44% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on July 23, 2025 offering an Overweight rating for the stock and assigned a target price of $71 to it. Coverage by Morgan Stanley stated Abivax ADR (ABVX) stock as an Equal-weight in their note to investors on March 20, 2025, suggesting a price target of $12 for the stock. On December 04, 2024, JMP Securities Initiated their recommendations, while on July 29, 2024, Laidlaw Initiated their ratings for the stock with a price target of $48. Stock get a Buy rating from BTIG Research on May 20, 2024.
